Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CPXX $2.25 0.5299 +30.81%
XLRN $32.03 2.9900 +10.30%
EPZM $29.88 2.7200 +10.01%
CYTR $2.91 0.2400 +8.99%
MACK $9.12 0.7200 +8.57%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

FATE $4.23 -0.5000 -10.57%
CERU $4.12 -0.2400 -5.50%
PVCT $0.94 -0.0400 -4.08%
IMNP $3.17 -0.1100 -3.35%
TLOG $3.86 -0.1300 -3.26%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Novartis Works with Bristol-Myers Squibb to Test Lung Cancer Drugs

(Reuters) Oct 6, 2014 - Swiss pharma group Novartis AG said on Monday it would work with Bristol-Myers Squibb Co to test the U.S. drugmaker's immuno-oncology drug Opdivo in combination with three of its own experimental lung cancer drugs.
read article 



AstraZeneca Whale Racing With Minnow to Develop Lung Cancer Drug

(Bloomberg) Oct 1, 2014 - The race to develop a new class of lung-cancer medicines is pitting one of the world's biggest drugmakers against a five-year-old startup.
read article 



Salix Calls Off Inversion Deal With Irish Arm of Drug Maker Cosmo

(New York Times/DealBook) Oct 3, 2014 - Salix Pharmaceuticals of North Carolina said on Friday that it had called off an inversion deal in which it would have acquired the Irish arm of an Italian drug maker and reincorporated overseas for tax purposes.
read article 



Societies Urge SGR Repeal in Lame-Duck Congress

(Medscape Medical News) Oct 2, 2014 - Politics killed a bipartisan bill to repeal Medicare's notorious sustainable growth rate (SGR) formula for setting physician pay in March, but 3 medical societies are urging its revival in this year's lame-duck session of Congress, when politics is expected to take a back seat.
read article (free registration required) 



EMA Remains Under Fire for its Policy on Disclosing Clinical Trial Data

(Wall Street Journal/Pharmalot blog) Oct 3, 2014 - After protracted debate and controversy, the European Medicines Agency has adopted a new policy on disclosing clinical trial data, which was designed to assuage concerns that important safety and effectiveness information was being kept out of reach at the expense of patients.
read article (paid subscription required) 



UnitedHealth's Latest Blow To Fee-For-Service Medicine: 6 Percent Off Doctor Costs

(Forbes) Oct 2, 2014 - As the Affordable Care Act, government and private insurers push doctors and hospitals away from fee-for-service medicine, the nation’s largest insurer, UnitedHealth Group says it’s seeing more results.
read article 



12 Exciting Cancer Breakthroughs You Should Know About

(FOXNews.com/Self magazine) Oct 3, 2014 - Exciting breakthroughs are in the works, and these women are giving us hope.
read article 



ExxonMobil Commits $10 Million to MD Anderson’s Cancer Prevention and Control Initiative

(MD Anderson) Oct 2, 2014 - ExxonMobil today announced a $10 million grant to MD Anderson Cancer Center’s Moon Shots Program, an unprecedented, comprehensive initiative to significantly reduce deaths from cancer.
read press release 



Specific Clinical Trial Methodology Needed for Rare Cancers

(Rare Cancers Europe) Oct 2, 2014 - A consensus paper published in the Annals of Oncology today by Rare Cancers Europe (RCE) calls for new methodologies to be applied to clinical studies in rare cancers.
read press release 



Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

(CNNMoney) Oct 3, 2014 - Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.
read article 



CytRx Gets Multiple Orphan Drug Designations For Aldoxorubicin

(NASDAQ/RTTNews.com) Sept 29, 2014 - CytRx Corp. Monday said the U.S. Food and Drug Administration or FDA has granted multiple orphan drug designations for its drug candidate, aldoxorubicin, in three indications, which include glioblastoma multiforme or GBM, small cell lung cancer and ovarian cancer.
read article  



Combating Cancer

(FT.com Special Report) Sept 26, 2014 - A wave of drugs that harnesses the body’s immune system is fuelling optimism that science is finally closing in on one of its greatest adversaries...and much more.
download pdf (free registration required) 



Hospitals React To Proton Therapy Questions

(Kaiser Health News) Oct 1, 2014 - Three hospitals react to KHN's story on proton therapy with the statements:
read article 



IceCure Tests Its Freeze Technology on Malignant Breast Tumours

(Reuters) Oct 1, 2014 - IceCure Medical Inc, whose technology destroys benign breast tumours by freezing them, is starting trials in the United States to test the product's effectiveness on malignant breast tumours, its chief executive said.
read article 



Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma

(TheStreet) Oct 3, 2014 - Unless Seattle Genetics can prove that using Adcetris immediately after stem cell transplant prolongs survival, the FDA won't approve a label expansion and the drug's use won't increase.
read article 



Breast Cancer Drug Sales Will Almost Double by 2023, Says IMS

(PharmaTimes [UK]) Oct 2, 2014 - Sales of breast cancer treatments are set to increase by an average of 5.8% a year in nine major markets, increasing from a value of $9.8 billion in 2013 to $18.2 billion by 2023, according to new forecasts from IMS Health.
read article 



Institute for Patient Access Releases “Protecting Cancer Care” White Paper

(DigitalJournal.com) Oct 3, 2014 - A white paper released by the The Institute for Patient Access explores how insurers’ cost-saving strategies may impede cancer patients’ access to the care they need.
read article 



'Parity' Laws for Costly Oral Cancer Drugs Not a Solution

(Medscape Medical News) Oct 2, 2014 - The laws have been applauded by many, including physicians and patient advocates, for reducing the cost of oral chemotherapy for cancer patients. So why are they being criticized by a trio of experts?
read article (free registration required) 



Heat Biologics, Inc. Completes Enrollment of Phase 1 Clinical Trial of Vesigenurtacel-L for the Treatment of Bladder Cancer Required to Advance to Phase 2

(NASDAQ) Oct 2, 2014 - Heat Biologics, Inc. announced today that it has dosed the ninth and final patient required in the Phase 1 portion of its Phase 1/2 clinical study for Vesigenurtacel-L (HS-410) in patients with high-risk non-muscle invasive bladder cancer.
read article 



Delcath Commences U.S. Phase 2 Study of Melphalan Hepatic Delivery System in Primary Liver Cancer

(Delcath) Oct 2, 2014 - Delcath Systems, Inc. today announced the opening of its United States (U.S.) Clinical Development Program for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
read corporate press release 



Cancer-Detecting Yogurt Could Replace Colonoscopies

(MIT Technology Review) Oct 2, 2014 - A spoonful of yogurt could soon offer a cheap and simple way to screen for colorectal cancer.
read article 



Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma

(NCI) Oct 2, 2014 - In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardless of whether they subsequently received maintenance therapy with rituximab or were retreated with rituximab only when there was evidence of disease progression.
read article 



NCI Scientists Find Protective Mechanism Against Cancer in the Cells of Progeria Patients

(NCI News Note) Oct 2, 2014 - NCI scientists have studied cells of patients with an extremely rare genetic disease that is characterized by drastic premature aging and discovered a new protective cellular mechanism against cancer.
read article 



Osteoporosis Treatment May Also Benefit Breast Cancer Patients

(McGill Reporter [Montreal, Canada]) Oct 2, 2014 - A new study, published in this month’s issue of the Journal of the National Cancer Institute (JNCI), is among the first to link bisphosphonate (a common osteoporosis medication) use with improved survival in women with breast cancer.
read article 



Researchers Discover Gene That Can Predict Aggressive Prostate Cancer at Diagnosis

(MD Anderson) Oct 2, 2014 - Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.
read press release